|
Case no
|
Class
|
Cycles*
|
Response
|
BCOR mutations (VAF)
|
Concomitant mutations
|
|---|
|
1
|
RAEB-t
|
2
|
CR
|
BCOR/4/C925Y (51%)
|
DHX9; WT1
|
|
2
|
RAEB1
|
6
|
CR
|
BCOR/11/K1452X (60%)
|
DNMT3A; ROBO1; STAG2
|
|
3
|
RAEB2
|
4
|
CR
|
BCOR/8/R1323W (50%)
|
NPM1
|
|
4
|
CMML1
|
3
|
CR
|
BCOR/8/K1339N (33%)
|
ASXL1; MPL; TET2; UPF3A
|
|
5
|
RAEB1
|
4
|
mCR + HI
|
BCOR/4/A619fs (16%)
|
PHF6; RUNX1; TET2
|
|
6
|
RCMD
|
3
|
CR
|
BCOR/4/Y361fs (85%)
|
NRAS; ROBO1; RUNX1; U2AF1
|
|
7
|
RCMD
|
4
|
CR
|
BCOR/12/R1547*(49%)
|
ASXL1; RUNX1; SRSF2
|
|
8
|
RAEB1
|
4
|
mCR
|
BCOR/4/p819-819del (74%)
|
DNMT3A; IDH2; ROBO1; RUNX1
|
|
9
|
RAEB2
|
4
|
CR
|
BCOR/7/R1165X (29%)/11/C4326 + 1C > A (56%)
|
CEBPA; DNMT3A; RUNX1; STAG2;TET2; U2AF1
|
|
10
|
RAEB2
|
4
|
NR
|
BCOR/7/P1101fs (65%)
|
ITIH3
|
|
11
|
RAEB2
|
4
|
CR
|
BCOR/4/V912fs (32%)
|
ASXL1; STAG2
|
|
12
|
RCMD
|
2
|
NR
|
BCOR/4/P483L (48%)
|
DHX9; EZH2; IDH1; U2AF1
|
|
13
|
RAEB2
|
4
|
mCR + HI
|
BCOR/4/T738fs (46%)
|
EZH2; MPL; RUNX1
|
|
14
|
CMML2
|
2
|
NR
|
BCOR/4/P483L (100%)
|
None
|
- *The induced decitabine cycles number means the course number of continuously accepted decitabine treatment (the durations between courses did not exceed 30 days); For the CR achieved patients with less than 4 induced courses. (No. 1, 4 and 6), the patients rejected continuously decitabine usage by themselves
